HIV/AIDS remains a major public health threat worldwide, with an estimated 39.9 million people living with the disease at the ...

NB.1.8.1. or “Nimbus” — may cause painful sore throats, earning it a new nickname: “razor blade throat” COVID.

If left untreated, the disease can lead to severe, long-term symptoms, and life-threatening issues like heart failure, ...

Viewers were particularly heated about the alleged cold sore after the "Got Wood ... A full STI panel typically includes testing for HIV, syphilis, hepatitis B and C, gonorrhea, and chlamydia, said ...

Why FDA approval of new HIV prevention drug is a big deal The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

A second study reported the twice-a-year injections lowered the HIV infection rate by 96% in groups of cisgender men and gender-diverse people in the U.S., Argentina, Brazil, Mexico, Peru, South ...

FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If approved, the shot—lenacapavir—would be given twice a year and ...

June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking a major advance in battling AIDS. Yeztugo was approved by the FDA ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV.

Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.